Total Pageviews

Thursday, 6 February 2014

HCL Corp forays into healthcare, launches India's first nation-wide networked multi-specialty clinics under HCL Avitas

HCL Corporation, the parent company of HCL Technologies and HCL Infosystems, has forayed into the healthcare sector with plans to be one of India's largest healthcare service providers. The new business entity, HCL Healthcare will address the entire spectrum of healthcare needs including providing healthcare delivery, innovative medical services, products and training to meet the growing need for quality healthcare.

Accordingv to Shiv Nadar, founder & chairman, HCL and Shiv Nadar Foundation, education, healthcare and technology will be the key enablers of India's future progress and growth. “Over the last 38 years, HCL has been at the forefront of technology and innovation. I have personally been committed to the cause of education through the Foundation for 20 years,” said Nadar adding that the company's entry into healthcare is an area of paramount national importance.

Kickstarting the venture, the company has launched a subsidiary called HCL Avitas in affiliation with Johns Hopkins Medicine International. Offering a of healthcare delivery offerings, HCL Avitas is positioned as India's first nation-wide networked multi-specialty clinics. The clinics will adopt global best practices for medical quality and training using evidence-based systems and integrating advanced technology to provide unmatched patient experience and outcomes.

Steven J Thompson, CEO, Johns Hopkins Medicine International, said, that HCL was a strong and trusted brand with a steadfast commitment to transform healthcare in India. “Together with HCL Avitas, we hope to establish a new paradigm in patient-centered care in India,” said Thompson.

HCL Healthcare observed that India has a shifting disease burden that is influenced by changing lifestyles and that this need is grossly underserved. “Our technology expertise and the ability to create scalable institutions will help us institute new benchmarks in healthcare delivery in India. Creating an organised technology-led health system that will be the long-term care partner is our immediate goal. HCL Healthcare intends to be that partner and provide patient-centered care for over 20 million people by 2020,” said Shikhar Malhotra, vice chairman, HCL Healthcare.

In the launch phase, HCL Avitas will establish a network of multi-specialty clinics across the country starting with the National Capital Region. Harish Natarajan, chief executive officer, HCL Avitas, said, “Technology is our strength – our clinics will all be networked giving patients access to their medical history and to the best specialists available in our system. Through our association with Johns Hopkins, we will bring in global best practices and the best evidence-based systems. In the next 5 years, we expect to have over 1500 doctors in our network across various cities in the country,” said Natarajan.

Wednesday, 22 January 2014

Banknotes issued prior to 2005 to be withdrawn: RBI Advisory


The Reserve Bank of India on January 22, 2014, advised that after March 31, 2014, it will completely withdraw from circulation all banknotes issued prior to 2005. 

In a note on its website, RBI said that from April 1, 2014, the public will be required to approach banks for exchanging these notes. Banks will provide exchange facility for these notes until further communication. 

The Reserve Bank further stated that public can easily identify the notes to be withdrawn as the notes issued before 2005 do not have on them the year of printing on the reverse side. (Please see illustration below)

 The Reserve Bank has also clarified that the notes issued before 2005 will continue to be legal tender. This would mean that banks are required to exchange the notes for their customers as well as for non-customers.

From July 01, 2014, however,  to exchange more than 10 pieces of Rs 500 and Rs 1,000 notes, non-customers will have to furnish proof of identity and residence to the bank branch in which she/he wants to exchange the notes.

The Reserve Bank has appealed to the public not to panic. They are requested to actively co-operate in the withdrawal process.

Friday, 17 January 2014

Ranbaxy's biggest bulk drug unit under US FDA scanner

This story first appeared in DNA Money edition on Tuesday, January 14, 2014

Troubles do not seem to end for Ranbaxy Laboratories, which saw its shares tank 9.47% on Monday after one of its key facilities at Toansa, Punjab, was slapped with Form 483 by the US Food and Drug Administration (FDA).

Form 483 is issued at the conclusion of an inspection when investigators observe any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic Act and related Acts.

The shares of Ranbaxy, the biggest Indian drugmaker by sales, opened at Rs 466 on Monday and reached a low of Rs 420 before closing the day at at Rs 438.80,  down 5.58% from the previous close.

This is the second biggest fall since September 2013 when the stock had lost 30.27% of its value following an import alert on its Mohali plant by the US FDA for violation of current good manufacturing practices.

In a note to the exchanges, Ranbaxy said, “It is assessing the observations, and will respond to the US FDA in accordance with the agency’s procedure to resolve the concerns at the earliest.”

While Ranbaxy management did not share any production related details, industry experts said the plant manufactures around 70-75% of its API requirements.

Under the Form 483 process, the company would now have to respond with its corrective action plan and implement it expeditiously or face an import alert.

Sarabjit Kour Nangra, vice-president, research-pharma, Angel Broking, said, “During the second quarter of calendar year 2013, its other key facility at Mohali came under US FDA import alert. With this plant also under scanner, it would have impact on the operations of the company in the US, unless it can compensate for the same at the earliest and mange a smooth supply of key raw materials,” said Nangra.

She said more clarity is awaited from the Ranbaxy management in order to ascertain the exact impact on the financials, especially operating profit margins.

“Until then, the company could trade at a huge discount to its peers,” said Nangra.

Getting US FDA clearance will be crucial for Ranbaxy considering all of its India-based factories are currently banned by the regulator from exporting medicines to the US, its largest market.

Last week Ranbaxy inked a licensing pact with EPIRUS Switzerland GmbH for BOW015, a biosimilar version of Infliximab, prescribed to treat rheumatoid arthritis, and said the product will be introduced in India and other emerging markets.

Ranjit Kapadia, senior vice-president - pharma, Centrum Broking, said the molecule has only completed Phase 3 studies. “It would take 12-18 months to get regulatory approval and commercialise the product in India,” he said.

Will Wockhardt turn rocket for its lone Mutual fund believer?

My colleague Nupur Anand is the lead writer of this story appearing in DNA Money edition on Monday, Janart 13, 2014.

Last time when the Wockhardt shares shot up a whopping 350% was in 2012 after the drug firm successfully came out of debt restructuring.

This time buffeted by issues with the US Food and Drug Administration, the stock is again in doldrums -- between April and December it lost 83%, down to a new low of Rs 339.85 from Rs 2,024.90 at the start of the fiscal.

And now rooting for an encore is Prashant Jain, chief investment officer of HDFC MF, India’s largest fund house, who known for taking contra calls and unusual bets that have paid off.

As Wockhardt stock nosedived, several retail investors and mutual fund houses started dumping it.

In the same period, Jain quietly picked up the pharma firm’s shares.

Till April last year, HDFC MF had zero shares of Wockhardt, whereas other mutual funds held 10.34 lakh shares.

By September end, HDFC has 13.59 lakh shares, a whooping 97% of the total shares held by mutual fund houses.

Out of the total 1.36% shares of Wockhardt held by MFs, Jain alone holds 1.29%.

Under Jain’s watch, the asset under management of HDFC MF have grown to mammoth size of Rs 108,990 crore.

And market experts believe that this contra call by Jain may pay off.

An expert with a foreign brokerage said, “The rationale behind Prashant Jain’s optimism has to do with his philosophy on finding deep value stocks which he can hold, and expect higher value to unravel when it tides through difficult times. To me, the recent stock correction factors a worst-case scenario.”

A pharma analyst from a leading domestic brokerage added, “Fundamentally, despite trouble with US FDA, the residual business would have enough earnings power to justify current price. The current balance-sheet health is much stronger than ever, and hereon there can only be upside to earnings outlook. The kind of turnaround Prashant Jain has seen in Aurobindo could be something he is betting on in case of Wockhardt, once the regulatory issues are tackled.”

Bad times for Wockhardt started in May after the USFDA put an import alert on its Waluj plant and intensified between May and November, when the company being hauled up four more times by the US and the UK drug regulators.

Sarabjit Kour Nangra, VP-research, pharma, Angel Broking also believes that Jain’s bet may pay off.

“The Wockhardt stock took significant beating last year and has probably gone through the worst times. But one needs to also take into account that the company successfully came out of the financial mess in the years before that and Jain is certainly betting on its revival from the US FDA and UK Medicines and Healthcare Products Regulatory Agency issues,” said Nangra.

“One also needs to remember that Wockhardt is one of the biggest players in the pharma industry and investors with a long-term view would certainly take exposure as the risk-reward is huge,” she said.

Wockhardt stock has been recovering slowly and is now trading at Rs 424.95, already up 25% from the December low of Rs 339.85.

Wockhardt’s foreign drug regulator alerts

May 2013 - US Food and Drug Administration import alert on Waluj Plant

July - UK Medicines and Healthcare Products Regulatory Agency (UK MHRA) import alert on Waluj plant

Oct - UK MHRA withdraws Good Manufacturing Practice (GMP) certificate for Daman plant

Oct - UK MHRA withdraws GMP for Chikalthana plant

Nov - US FDA import alert on Chikalthana plant

Dec - US FDA import alert on Chikalthana and Waluj units for veterinary drugs

Friday, 10 January 2014

Now, IHCL aligns its United Kingdom hotels with Taj brand

This story first appeared in DNA Money edition on Wednesday, January 08, 2014.

Indian Hotels (IHCL), Tata’s hospitality business vertical, has rebranded two of its hotels in the United Kingdom (UK), aligning them with its luxury positioning in the international hospitality market.

The UK hotels will now be promoted within the Taj group’s portfolio of luxury hotels, resorts and palaces.

Taj management said it now has sole ownership and management, as well as operational and marketing control, of both properties.

The over a century old Crowne Plaza London - St James, a property located in central London and featuring 340 guestrooms and 21 suites, has been renamed St James’s Court, a Taj Hotel. While the published rate for a standard room at this hotel is £495 (around Rs 50,500) for a night’s stay, the best available rate as shown on its website is £119 (Rs 12,100) including the value-added tax or VAT.

Similarly, 51 Buckingham Gate, Taj Suites & Residences (pictured, below; 86 luxury suites and residences) has been re-branded Taj 51 Buckingham Gate Suites and Residences. With a published rate of £720 for a base category room, the hotel’s website shows £360 and £324 as best available and early bird (non-refundable) rates for a night’s stay.

Raymond Bickson, MD and CEO of the Taj group, said that the rebranding comes at an exciting time for the increasing strategic links between India and the UK. “We are delighted to have the opportunity to restore these iconic hotels that have more than a century of heritage.”

Deepa Harris, senior VP-global sales and marketing, the Taj Group, said that the success of the two London hotels has provided impetus to consolidate Taj’s brand presence in the UK, an important source market where the Tata group has had a presence for over a century, and is now the UK’s largest manufacturing sector employer and one of its largest foreign investors.

Both hotels have undergone phased renovations at considerable (but undisclosed) investment from the Taj group.

Taj will add to the Tata brands portfolio in the UK that includes Jaguar, Land Rover, Tata Steel Europe (formerly Corus) and Tetley Tea.

Mylan ropes in Biocon honcho Bamzai

This story first appeared in DNA Money edition on January 03, 2014.

Post the US parent Mylan Inc accomplishing the $1.75-billion acquisition of Agila injectables businesses from Strides Arcolab in December last year, the Indian subsidiary is now understood to be getting on board a top-notch pharma industry veteran to lead its Indian business activities.

Touted to be taking up a leadership position with Mylan India is Rakesh Bamzai, (pictured) who recently quit as president of Bangalore-based biopharmaceutical company, Biocon Ltd, after 19 years of association.

“He (Bamzai) is joining Mylan India,” confirmed an industry source familiar with the move.

Bamzai could not be reached for a comment on this move, while Mylan India did not respond to a email seeking confirmation on the same.

While details about the leadership position at Mylan India is still unknown, industry sources say it could very likely be a similar position Bamzai held at Biocon or possibly a higher management position.

Interestingly, in a notification to the exchanges, Biocon had said that Bamzai has decided to leave the organisation to accept a new leadership role.

“Rakesh has decided to take up a very senior and challenging leadership assignment,” said Kiran Mazumdar-Shaw, chairperson and managing director, Biocon.

Media reports had indicated that Bamzai was widely considered to be the next chief executive officer (CEO) of Biocon despite the fact that the biopharmaceutical company was going through a process of extensive reorganisation.

Mylan Labs’ current CEO and managing director, B Hari Babu, has been associated with the company since May 2001.

Hari is responsible for all of Mylan Labs’ operations including research and development, active pharmaceutical ingredient (API) and finished dosage production, supply chain management, environmental health and safety, sales and marketing, human relations and finance.

Mylan Labs is one of the world’s largest manufacturers and suppliers of over 150 APIs.  

Among a wide range of therapeutic categories being catered to by Mylan include antibacterials, central nervous system agents, antihistamine/anti-asthmatics, cardiovasculars, antivirals, antidiabetics, antifungals, proton pump inhibitors and pain management drugs.

Update from Mylan Inc.

Mylan Inc (Nasdaq: MYL) announced that Rakesh Bamzai has joined the company and has been appointed president, India Commercial and Emerging Markets.

Bamzai has more than 20 years of experience in the Indian and global biopharmaceutical industry. Prior to joining Mylan, he was president of Marketing at Biocon, where he played a key role in building the company's global biopharmaceutical business. He had overall responsibility for active pharmaceutical ingredients (API) and branded formulations and managed a team of more than 2,000 people across functional areas and geographies.

Through the years, he also spearheaded many strategic partnerships that enabled the organization to gain wider global access and greater market penetration for its biopharmaceuticals business. Bamzai also led Biocon's foray into branded formulations and built many successful brands across therapies in India and Gulf Cooperation Council states.

Mylan President Rajiv Malik commented, "We were extremely pleased when Rakesh asked to join our company. Many of us at Mylan have had a firsthand opportunity to work with Rakesh over the course of our strategic partnership with Biocon and have observed his strong business and marketing acumen, his strategic insight and outstanding leadership skills. In this new role overseeing all of Mylan's commercial operations in India and emerging markets, we believe that Rakesh will add significant value to Mylan."

Bamzai said, "I have had the privilege of collaborating with Mylan during my time at Biocon, and I am excited about the significant opportunities I see for the company in India and other emerging markets. I believe Mylan's commitment to quality and to setting new standards for innovation, reliability and service for patients and physicians in India will further distinguish Mylan from its peers. I look forward to supporting Mylan's continued expansion and differentiation in these exciting growth markets."

Bamzai graduated from the University of Mumbai (Department of Chemical Technology).

Fairmont Raffles looking to wind up India operations

A version of this story first appeared in DNA Money edition on January 01, 2014.

Canadian hotel company Fairmont Raffles Hotel International (FRHI) is considering winding up its India operations as the cost of operating a hotel management company in India is becoming unviable, industry sources said.
It may re-enter when overall environment gets more conducive for business, they said.

“The hotel management company has begun giving out feelers to asset owners on its plans to withdraw from India. A communication has been sent out by the company to hotel asset partners with whom it has signed Letters of Intent for future launches expressing its intentions. The same is true for its operational properties, too,” said an industry source privy with the development.

It is also learnt that FRHI has already shut its development office in India and has moved some of the staff to its Dubai office. The development office typically identifies and initiates discussions with hotel asset owners and enters into LoIs and management contracts.

“However, slowdown in development activities forced the hospitality firm to relocate operations,” said another source.

FRHI, however, denied all market talk of its India exit.

In an emailed response, the hotel operator said, “FRHI Hotels & Resorts continues to view India as a core strategic market and we look forward to growing our presence in the country in the future. We have enjoyed a very successful entry into the market with Fairmont Jaipur, and remain fully committed to operating in this key domestic market. Additionally, we see the Indian market as critical not only for our growth in India but also for outbound travel to our hotels globally.”

Fairmont Raffles Hotel International is a global operator of hotels in the five-star luxury category with brands like Fairmont, Raffles and Swissotel with more than 100 properties. 

The company had entered India in 2010-11 with plans to operate 40 hotels in five years. The plan was to operate up to six hotels under Raffles brand, about 8 to 12 under Fairmont and around 20 Swissotels under management contract in India, a top official had said then.

However, it has only two operational hotels so far -- one each under Fairmont (Jaipur) and Swissotel (Kolkata) brands. Its third brand Raffles is yet to debut in the market.

Its Swissotel branded five-star deluxe resort at Calangute in Goa was deflagged (within six months of the launch) in September 2013.

The development pipeline had two more hotels under the Swissotel brand in Gurgaon/Noida and Bangalore (Whitefield) that were to be operational in 2013 – the Swissotel website now has 2015 and 2016 as the year of launch.

Similarly, work on a Swissotel property at Mumbai's Andheri-Kurla road area has been stalled for almost a year now and is unlikely to meet the 2015 launch date. The fate of Fairmont branded hotel in Hyderabad is uncertain as well.

Sun Pharma's Sudhir Valia picks 1.41% stake in Ranbaxy Labs

Sudhir Vrundavandas Valia, who is executive director with Sun Pharma, has picked up 1.41% stake in Ranbaxy Laboratories. The stake was bought by Mumbai-based Silverstreet Developers Llp in which Valia is partner.

Approximately 59,67,542 valued at a little over Rs 247.65 crore (average share price at Rs 415 for the December quarter) are being held by Silverstreet according to shareholding pattern released by Ranbaxy for the quarter ended December 2013.

Ranjit Kapadia, senior vice president - Pharma, Centrum Broking Ltd, said, "Sudhir Valia’s move seems to be that of  a strategic investor in the company from long-term perspective. From Sun Pharma point of view there is no change, as the shares have been acquired in his personal capacity."

In another development, Ranbaxy Laboratories has inked a licensing pact with EPIRUS Switzerland GmbH for BOW015, a biosimilar version of Infliximab, prescribed to treat rheumatoid arthritis. The product will be introduced in India and other emerging markets, Ranbaxy said in a statement.

Kapadia is of the opinion that the licencing agreement will help Epirus market its biosimilar in India through a large field force of Ranbaxy without setting up own field force and distribution channel. "However, the molecule has recently completed Phase 3 studies and it would take 12-18 months to get regulatory approval and commercialise the product in India," said Kapadia.

Zydus Cadila gets US nod for two drugs


Drug firm Zydus Cadila has received approval from the US Food and Drug Administration (USFDA) to market Sirolimus tablets 0.5 mg with 180 days of marketing exclusivity Sirolimus. As per the IMS data in 2013, the sales of Sirolimus 0.5 mg is estimated at USD 11.7 million and the total market for Sirolimus stood at around USD 203.8 million.

The Ahmedabad-based firm has also received USFDA approval to market Duloxetine delayed release capsules in different strengths of 20 mg, 30 mg and 60 mg. The sales for Duloxetine was estimated at USD 5.5 billion in 2013.

While Sirolimus tablets are immunosuppressant drugs used to prevent rejection in organ transplantation, Duloxetine delayed release capsules fall in the anti-depressants segment.

Tuesday, 7 January 2014

Only 10-15 lakh households in India can afford an apartment worth Rs 1 core: Shashank Jain, executive director, PwC

An version of this Q&A first appeared in DNA Money edition on Monday, January 06, 2014.

Shashank Jain, executive director, PwC India in conversation with Ashish K Tiwari speaks of the perils dogging the Indian residential realty sector and why the market is the way it is. Edited excerpts..
 
Unaffordable housing is said to be the key reason for lack of demand and oversupply scenario in key Indian metros. What is your take on it?

There are larger issues involved in terms of resolving this – not only with the developers but with the entire eco-system. Building affordable houses starts with two things, land and infrastructure and both go hand in hand. Land prices will always be high in places where infrastructure is already developed leading to significantly high starting input cost for the developer. So land cost in cities like Mumbai and National Capital Region (Delhi and Gurgaon) could form over 50% of the total project cost. And where the infrastructure is not developed, there are very few takers for the residential projects thus raising questions on their viability. So it's like a chicken and egg situation.

Unfortunately we haven't had a situation where both central and state governments have taken this pro-actively and have focussed on building infrastructure in a greenfield way – infrastructure has always played a catch-up role with urbanisation and development and not the other way round.
Residential market would pick up if you have a commercial catchment area in the vicinity. People would prefer buying into a residential project if their work place is close by as well. While a developer may build affordable housing, if the project is far away from the main city and if people have to travel over 2 hours one way to get to their place of work, the development will be a non-starter. So developing of commercial catchments is crucial for micro markets to pick up the way one would want it to happen.

A holistic approach with infrastructure, commercial, corporate and residential units around it is thus essential when developing cities and micro markets. All of it has to happen simultaneously.

But residential prices are unaffordable even in the extended suburbs of cities where there is very little or absolutely no infrastructure development.

I'd say that has also got to do with the availability / scarcity of resources (primarily land) and the situation is more severe in the Mumbai Metropolitan Region (MMR) because of its unique position / geographical layout.. However, if you look at the National Capital Region (NCR), it has expanded on all sides and offers housing across all price points. Similar is the case with Chennai or Bangalore markets which can expand horizontally. While it may not be completely affordable, one can possibly look at owning an apartment after stretching (finances) a bit.

Unfortunately, in India we are in a situation where if you look at from a developer's perspective, the input cost is so high that it makes the starting point unviable/unaffordable for the realtor as well. For a developer land is inventory and an essential resource for a long-term play of say 10-15 years or more. This means land prices have already seen significant appreciation at places where a common man would actually think of buying / residing. That's because the developer is thinking five to seven years ahead and focuses on acquiring land that may not be uninhabitable at present. So acquisition of land and development always plays a catch-up game and land prices are hence always ahead of the curve that way thus raising a big question on the affordability factor.

Also, income levels of potential home buyers haven't kept pace with the extent of increase in realty rates in the last 3-5 years.

That's correct. At max, salary levels on an average would have gone up marginally when compared to  overall inflationary increase. Leaving aside the exceptional cases, that's generally the kind of increments people would have got in the recent past. However, if you look at real inflation at the consumer level, it's far higher. So from a cash available to sustain I'd say it's a negative growth situation.

Now consider that scenario vis-a-vis developer's input cost for building a house, that's increasing year-on-year too. This is clearly evident from the fact that the primary market, which is is the key driver for affordability – where one can get into buying a house with lower capital requirement – is seeing an increase to the tune of 10-20% every year. Given the overall economic uncertainties of the last few years, salary levels certainly haven't kept pace with it and that definitely is a key challenge.

According to Apnapaisa.com estimates, a monthly income of over Rs 1.5 lakh is required to be able to purchase (through a home loan) a residential apartment worth Rs 1 crore. How many people in the working class would really qualify?

The National Council of Applied Economic Research (NCAER) and Centre for Macro Consumer Research do come up with such data. The last I recollect, there is a a bracket of households earning Rs 12.5 lakh and above and that number is just 1% of the total households. A quick math would reveal that if we are about 120 crore people and taking an average household size of five, then we are talking about 24-25 crore households in the country.

The reason I'm focussing on households is because buying a residential apartment is a household decision and not an individual decision. If 1% out of those many households are earning more than Rs 12.5 lakh annually we get a figure of 25 lakh households spread over the country. If we increase the Rs 12.5 lakh limit to say Rs 15-20 lakh I think it could be even half. So we are talking about only 10-15 lakh households who possibly be earning that kind of a money to afford an apartment worth Rs 1 core.

This profile of households would majorly be in the top four or five metros of the country that again brings back to your question about affordability. When people who can afford are concentrated in certain geographies, prices in such markets would shoot up. Which sort of makes it a vicious circle again, because wherever developers are building affordable housing people living there do not have the means to buy into such projects.

Another concern for home buyers is of the uncertainty in terms of delays / deliveries of housing projects be it in the city, suburbs or extended suburbs. It only adds to the dilemma (to buy or not to) and related sufferings.

Real estate is one of the few sectors wherein delays in a project execution actually gives more returns from a buyer's perspective. At a macro level, by making a booking and not paying for that owing to the project delay, I actually get an appreciation on the investment. That anomaly needs to get corrected at a macro level.

That anomaly could be true for the investor community. The end-user however is at the receiving end incurring rental and EMI expenses at the same time while fighting inflation...

I agree, the end-users are significantly impacted as a result of project delays. Unfortunately we are in a situation that in any project which gets launched, I'd think majority of the buyers are not end-users. It's a vicious circle. The investors are indifferent to any delays in the project as it helps them get better appreciation.

In fact, the registration numbers that get released every quarter, I'm told a large proportion of it is secondary sales.

The other related parameter in my opinion, is that in any micro market, if the secondary rates are Rs 1,000 to Rs 1,500 per square foot lower than what the developer is offering, that's a clear sign of an overheated market. Why would any project that's at an advanced stage of construction be sold at a lower rate as compared to a fresh launch? This is a clear indication that there aren't many takers in the market for projects that are significantly constructed and that clearly is an investor driven market.

But investors continue to drive the residential realty market thus giving the developer that much required initial cash flow.

There are two types of investors, one is the business community with element of unaccounted surplus being parked in the real estate sector. The government is trying to control it by imposing tax deduction at source (TDS) of 1% for an amount of Rs 50 lakh and more. Secondly, a significant chunk of investment is made by white collar executives especially in the metro micro markets. by This class of investors is putting their surplus income in second or third home and they don't have exit pressure. They have a steady stream of monthly income that helps support second or third home thus giving them a significantly higher holding power. That again brings back to the question that prices will not come down significantly.

Monday, 9 September 2013

Are hotel owner-operator marriages becoming flings? Now Swissotel pulls out of Goa property

An edited version of this story first appeared in DNA Money edition on Monday, Sep 9, 2013.

With relationships between Indian hotel asset owners and international hotel operators getting sour, for various reasons, the Indian hospitality market is set to see an increase in the instances of such marriages hitting a rocky patch.

Emulating the split between Phoenix Mills and Shangri-La Hotels that happened last week, another foreign hotel operator has decided to call it quits.

This time it is Zurich-based Swiss hospitality chain Swissotel Hotels & Resorts which is pulling out of its five-star deluxe hotel at Calangute in Goa. The Goa property is owned by Bangalore-based Convention Hotels India Pvt Ltd (CHI).

Officials of both CHI and Swissotel could not be reached for a comment.

However, Swissotel’s website confirmed the development saying, as of September 9, 2013, Swissotel Hotels & Resorts will no longer manage Swissotel Goa. The hotel will be renamed and operated by the owner.

The international hotel chain -- Swissotel -- is owned by FRHI Holdings Limited, a leading global hotel company with 102 hotels and resorts worldwide under the Raffles, Fairmont and Swissôtel brands. The company also manages Fairmont and Raffles branded Residences, Estates and luxury private residence club properties.

Interestingly, Swissotel Goa was launched amidst great fanfare just six months ago i.e. March 2013 and, in most likelihood it is the shortest owner-operator marriage the Indian hospitality market has seen thus far. The fling between Phoenix Mills and Shangri-La Hotels had lasted nine months.

Convention Hotels is currently developing four hotels in the country with a combined guestroom inventory of 715 keys. The company’s development pipeline includes a 35-room tented resort is under development at Kabini (Bangalore), a 220-room Holiday Inn hotel in Goa to be managed by Intercontinental Hotel Group (IHG), a 200-room Hilton Garden Inn to be managed by Hilton Worldwide and a 260-room Hyatt Place hotel in Bangalore that will be managed by Hyatt Hotels & Resorts.

Industry experts said the Indian hospitality market will see many more asset owner-hotel operator relationships turning sour, citing conflict of opinion (on business operations and expected returns on investments) as the key reason for the split.

Another possibility of a fall-out, industry sources said, will be between Shiva Satya Hotels which is developing a five-star hotel to be managed by IHG under its Crowne Plaza brand. The duo had signed a management agreement back in August 2008 and the hotel was to be operational in 2010. However, the project has got delayed significantly and there is no clarity on its completion timeline as yet.


Information Update:

Before launching under the Swissotel brand, the management contract for the Goa resort was signed with the InterContinental Hotel Group and was to be operated under the Holiday Inn Resort. However, Swissotel came in at the last moment and bagged the management contract.

As of now, this flagship hotel from the
Bangalore-based Convention Hotels India Pvt Ltd (CHI) has been re-branded as North16Goa.

Sunday, 8 September 2013

Hoteliers add over 800 guestrooms across India in two weeks

This story first appeared in DNA Money edition on Thursday, Sep 5, 2013.

The current financial environment may remain tough, but that has not deterred Indian hospitality industry – both Indian and international – from pushing ahead with new hotels. In all, approximately 827 new guestrooms were added in the organised hospitality sector in the last two weeks and a majority – approximately 60% – of them have come up in South India alone.

Some of the big names here include Indian Hotels Co (Taj Group), East India Hotels (Oberoi Group), Accor, Berggruen Hotels and the Panaromic Group.

While French hospitality major Accor opened a 131-room budget hotel under the ‘Formule1’ brand in Bangalore, IHCL from the Tata stable rolled out its 200-room upscale ‘The Gateway Hotel’ on the IT Expressway in Chennai. September thus far has seen three hotels being launched with a combined guestroom inventory of 496.

Earlier this week (September 2), the Oberoi Group threw open its 323-key five-star business hotel under the Trident brand in Hyderabad. Berggruen Hotels, promoted by US-based Berggruen Holdings, opened its first five-star hotel in Pune under the Keys Klub brand featuring 115 guestrooms while a 58-room premium hotel got christened United 21 in Hyderabad.

While it may appear as a sheer coincidence that almost half-a-dozen hotels have entered the Indian hospitality market at around the same time, experts said most of the projects have been under development for some time now. “Hotel chains ideally like to time their new launches and September being the shoulder month it makes for a sensible move. The Indian hospitality sector will enter the peak business season starting October going up to January/February and launching at this time will help them tap incremental business,” said Ashish Bharadia, senior consultant, Mahajan & Aibara Management Consultant.

There is unanimity that coming months will see more additions from the likes of Marriott, Starwood, Accor, Hyatt and IHCL.

For instance, Marriott International is set to open its account for its 297-room five-star deluxe JW Marriott hotel in Bangalore this month. Another 510-room JW Marriott hotel is slated to take off inside the DIAL Hospitality District in New Delhi. Marriott will also open a few Courtyard by Marriott branded hotels with a total inventory of 350-odd in cities like Bilaspur (104), Pune (180) and Agra (150), in addition to a 150-key Fairfield by Marriott in 2013-14.

Similarly, for Accor, it’ll be a 104-room Formule1 and 223-room Novotel hotel each in the Pune hospitality market this calendar year. Two more Novotel hotels, one each in Ahmedabad (180 room) and Goa (150 room) are likely to hit the market in 2013.

A 167-room Hyatt Regency is currently under construction in Ludhiana and projected to go live this year. Starwood Hotels and Resorts will take the curtain off a 323-room five-star hotel in Kolkata under the Westin brand and a 126-room Le Meridien hotel in Mahabaleshwar. Hilton Worldwide is in the process of opening DoubleTree by Hilton hotels in Jaipur (179), Bangalore (172), Pune (115) & Agra (102) and a Hilton Residences in Bangalore (243 rooms) in 2013.

Cement makers seen hiking prices in September

This story first appeared in DNA Money edition on Saturday, Aug 31, 2013.

Cement companies have decided to hike prices starting next month, according to some  dealers in the know. “It could be around Rs 50 per 50 kg bag in Mumbai,” said Peeyush H Shah, promoter, Shri Padmavati Enterprise, a Mumbai-based dealer.

The hike will be effective next week, he said, adding, “The increase, from what I understand, will be taken by all cement manufacturers”.

In a cement sector review on Friday, Mihir Jhaveri and Prateek Kumar, analysts with Religare Institutional Research, said that though some dealers have indicated about manufacturers pushing for hikes from September owing to input cost escalation and the rupee’s decline, the move is not sustainable given the weak demand scenario.

Based on their discussions with over 40 dealers across 30 Indian cities, the Religare analysts said cement prices took a sharp hit during August after remaining relatively stable during July. “Prices in regions have corrected in the range of Rs 10-50 per bag in both trade and non-trade segments. The north and central markets witnessed a sharp fall of as high as Rs 40-50 per bag for select brands. 

"In Andhra Pradesh, prices have corrected by Rs 60 per bag after sharp hikes of Rs 60-80 per bag in June. Other southern states have seen a milder decline of Rs 10-15 per bag. Declines in the western and eastern regions have been in the range of Rs 10-30 per bag,” the duo noted.

The decline was primarily led by increased supply due to the entry of new players, poor demand owing to a weak macro and shortage of materials (sand/brick), and good monsoons across most regions.

The current all-India trade segment average is pegged at Rs 280-285 per bag as compared to the estimated average of around Rs 290-295 per bag in the quarter ended June.

Cement prices in the non-trade segment were lower by Rs 10-20 per bag.
The decision to hike prices, industry experts feel, is certainly motivated by the fact that cement prices suffered significantly in July and August. And with input costs continuously on the rise, a price hike is the only way to stimulate demand and deal with the current slump in the market.

“Cement companies are expecting construction activity to increase considering the monsoon season is almost getting over, and are using this opportunity to bring prices back to the pre-monsoon levels,” said an analyst with a domestic brokerage.

Maintaining a cautious outlook on cement sector for the current quarter, the Religare analysts said that sluggish demand and weak pricing would likely keep profitability under pressure. Also, if prices fail to revive in September (with monsoons still prevailing in some regions), realisations are likely to be sharply lower again on a year-on-year basis, exasperated by last year’s high base due to delayed monsoons.

“With minimal benefits from lower international coal prices (owing to depreciation of Indian rupee), operating profit per ton (ebitda/t) of cement companies could see a quarter on quarter dip in the range of Rs 200-250 (depending on regions, but mid-caps likely to be hit more). The July-September quarter for the sector is also likely to remain muted, with sluggish volumes, weak pricing, cost pressures and a high base,” the analysts said.

A top official of a leading cement firm, however, denied any possibility of pan-India price hikes, saying it would more likely be a regional. “It’s very difficult to say if there will be a price hike in September. It is also the ‘Shraadh’ month and is not considered auspicious, so demand from the real estate sector will anyway be muted. As for festive season, I think there is still some time for that,” the official said.

Depreciating Indian rupee = 12% growth for domestic travel and tourism industry

My colleague Yuga Chaudhari co-authored this story appearing in DNA Money edition on Friday, Aug 30, 2013.

The past 10-15 days have turned out to be quite a surprise for Himmat Anand, founder, Tree of Life Resort and Spa in Jaipur. The 14 villas premium property has been receiving host of inquiries and bookings for the month of November and December, a phenomenon he’s not experienced in the past. “This never happened before because the domestic market usually reacts 2-3 weeks before the travel time,” said Anand.

The sentiment is pretty much the same among travel and tour operators in the country. In fact, experts are of the opinion that the domestic travel and tourism industry which has been growing exponentially in the past years despite economic slowdown is in for a big bounce this business season.

Ashwini Kakkar, executive vice chairman, Mercury Travels, attributed the impact of depreciating Indian rupee (INR) as a key reason for the increased optimism in the domestic travel market. “Domestic travel is set to benefit in a big way. The industry has been growing at 6% odd and it could certainly hit double digit this time around,” said Kakkar.

Anand agrees saying based on the current market scenario, growth in domestic tourism should be upwards of 12% if not more. He added, there is a shift in people’s mindset with a realisation that overseas travel will be challenging. As a result, they are planning and freezing their holidays across domestic destinations.

“In the near term I definitely see an increase in the of number of people choosing domestic travel over internatinal. In fact, a lot of bookings for our property have already come in for the first half of October. The increase in percentage terms this season will be anywhere between 8 and 10% year on year (yoy),” said Anand.

Echoing the sentiment are Regi Philip of travel company Cosmos Agencies and Jai Bhatia, chairman western region, Travel Agents Association of India (TAAI) who expect domestic travel to pick up this year during the holiday season.

In fact, Bhatia is of the opinion that people are also deferring their international travel plans as the INR continues to depreciate compared to euro and dollar. "Domestic travel is expected to get a boost this year as people may look at postponing their international travels," he said.

Industry experts are of the opinion that people are being very cautious and are generally scaling down all types of travel more so the international travel and are think twice before traveling abroad as everything has become expensive. According to Amrit Pandurangi, senior director, Deloitte in India, airlines are also not in a position to provide discounts as oil prices are going up. “International travel, in the absence of any serious airfare reduction, will see a reduction this year. Business travel overseas will also remain muted as companies are focusing on cutting costs," said Pandurangi.   

The general consensus this holiday season is that international travel will take a beating. Based on his interactions with the travel trade, Anand said, outbound tourism is seeing a drop in bookings to the rune of 20-30%. In fact, business to long-haul high-value (holiday packages ranging from Rs 80,000 to over Rs 1 lakh per person) destinations like US, UK and Europe has gone down probably more than 40% or so. Short-haul low-value destinations (holiday packages ranging between Rs 35,000 and Rs 50,000 per person) like Thailand and other Far East countries are seeing a drop of 10-15%.

However, outbound business to South Africa (SA) and Australia is still looking good as the Indian rupee (INR) hasn’t devalued so much (in these destinations) as compared to other currencies. In fact, just a few days back, SA started a very aggressive promotion for the Indian travellers highlighting the fact that the INR will still get them good value in SA.

As a result, bigger tour operators including the likes of Cox & Kings, Thomas Cook, Mercury Travels etc are proposing those destinations where the currency weakening has been of the similar order to the INR so that the impact is not felt by the traveller. “Destinations like Australia, South Africa, Brazil, Turkey, Mexico have seen almost similar devaluation in their currency when compared to the INR. So tourists are open to shifting preferences from say the US or Europe to South Africa or for that matter Australia,” said Kakkar.

With bookings for outbound travel are yet to happen coupled with the volatility in the exchange rate people are taking the wait and watch approach expecting the INR to stabilise and then take a call on their international plans.

Starwood, Marriott in race for Phoenix's Mumbai hotel

This story first appeared in DNA Money edition on Thursday, Aug 29, 2013.

While Phoenix Mills, the promoters of erstwhile Shangri-La hotel in Mumbai, have renamed the property Palladium Hotel for now, it is understood that the asset owners are in talks with global hospitality majors for a new management contract.

Global hospitality majors, including Starwood, Marriott and Hyatt, are said to be engaged in hectic negotiations with the asset owner, Pallazzio Hotels and Leisure, a unit of Phoenix Mills.

The current operator, Hong Kong-based Shangri-La Hotels & Resorts, handed over the hotel to Pallazzio on September 6, 2013. Earlier this week, Pallazzio and Shangri-La decided to mutually terminate the 20-year management contract after operating the luxury hotel for nine months.

Shishir Shrivastava, Group CEO and joint managing director, PML, did not respond to a query on the new international hotel operator/brand.

Industry sources said Starwood is a strong contender for the new management contract. Marriott and Hyatt are equally aggressive pursuing the matter, said one of the sources.

“These chains certainly are front-runners but then the hotel owners could be practically speaking to every possible operator,” the source said.

The current discussions with the asset owner are an indicator that a new hotel operator is yet to be finalised as against PML’s claims of already having someone on board.

Officials at both Starwood Hotels & Resorts and Marriott International said they were not in a position to comment.

Responding to a dna email, a Hyatt International spokesperson said, “The company is not in the race for the management contract at this time.”

There’s also some buzz that the hotel in question will join Starwood’s ‘Westin’ network. Interestingly, Pune-based Avinash Bhosle Group owns a 27% stake in PML’s Mumbai hotel and already has Starwood as the operator for its five-star hotel in Pune under the Westin brand. Its another upcoming property in Goa will also be managed by Starwood under the ‘W’ brand.

PML will have to take a final call on the new operator at the earliest.

This is because the Indian hospitality industry is set to enter the peak business season starting October and not having a hotel operator will make it very challenging for the asset owners.

Shangri-La, Phoenix Mills scrap management agreement for Mumbai hotel

An edited version of this story first appeared in DNA Money edition on Tuesday, Aug 27, 2013.

Nine months after operating the luxury hotel atop the Palladium Mall at Lower Parel in Mumbai, Hong Kong-based Shangri-La Hotels and Resorts is now calling it quits. Industry sources familiar with the development told dna that the hotel operator has decided to part ways with the Pallazzio Hotel and Leisure Ltd, which is the asset owning company and a subsidiary of BSE-listed Phoenix Mills Ltd (PML).

Shishir Shrivastava, Group CEO and joint managing director, PML, confirmed the separation though he denied that Shangri-La was walking out of the management agreement. “It is with mutual discussion that we have decided to terminate the contract. A new operator has been finalised already details of which will be made public shortly,” said Shrivastava. Being a mutual decision there will be no penalties levied for terminating the management contract with Shangri-La Hotels & Resorts which was for a period of 20 years.

Most of the hotel projects being developed by PML sit under a separate special purpose vehicles (SPVs). The Shangri-La Hotel, Mumbai is under Pallazzio Hotel and Leisure Ltd (a subsidiary of Phoenix Mills Ltd). The company has invested Rs 294.6 crore with a debt of Rs 652.6 crore. The overall project cost however is pegged at Rs 1,050 crore.

On what led the parting of ways between the two entities, industry sources said that a misalignment in their vision for the luxury hotel development was the key reason. This clearly is a case wherein the owner-operator did not get along a bit. The source said there was major disconnect between them for various reasons including significant delays and the hotel being partially developed in terms of total guestrooms and food and beverage facilities.

“The operator wasn’t very happy with the overall development. In fact, being a flagship hotel in Mumbai, Shangri-La also offered to buy out the asset owners and develop it as per their international standards but in vain. Finally, when nothing appeared to be working they decided to walk-out of the management agreement,” said the source.

The office of Farhat Jamal, area general manager (India, Sri Lanka and Maldives), Shangri-La Hotels and Resorts, also confirmed the development saying Shangri-La will withdraw from the management of the hotel on September 6.

Shrivastava said the hotel will continue to operate as an uber luxury hotel with several enhancements, new banquet facilities and further the signature restaurant Mekong and Libai Bar will launch as planned by mid September.

The new brand will have to be announced in the shoulder month itself as the Indian hospitality sector will enter the peak business season starting October.

After significant delays of approximately three years, the Shangri-La Hotel, Mumbai began receiving guests in sometime in the third week of December last year (2012). The delay led to its overall development cost of Rs 1,050 crore overshoot the planned expenditure by Rs 400 crore. Of the total 390 guestrooms and suites approximately 221 guestrooms were operational as on June 30, 2013. By August end this inventory was to increase to 300 rooms and another 90 rooms were to be added in a phased manner depending on the market demand.

With an average occupancy of 40% for the April-June quarter, the hotel enjoyed an average room rate (ARR) of Rs 8,473 which could have been better given the luxury positioning of the hotel. Room revenues for the first quarter of fiscal 2014 was Rs 5.9 crore versus Rs 5.8 crore for FY13.

Of the planned 11 restaurants, only three are operational while the balance were projected to be operational by September this year. Revenue from Banqueting and F&B in Q1FY14 stood at Rs 9.1 crore as compared to Rs 9.4 crore in four-odd months of FY13.

Sunday, 25 August 2013

Phoenix plans to raise Rs 1,000 crore

This story first appeared in DNA Money edition on Saturday, Aug 24, 2013.

Mixed-use developer Phoenix Mills Ltd (PML) is expected to soon kick-start the process of raising Rs 1,000 crore following shareholder nod for the proposal at its 108th annual general meeting.

The funds mobilisation will be in one or more tranches through a public issue or a private placement or a preferential issue or any other kind of public issue or private placement as may be permitted under applicable laws from time to time, PML said.

The PML management did not share any details about this fund-raising exercise. However, it is very likely that the company may use some portion of the Rs 1,000 crore towards repaying debt.
PML’s standalone debt as of June 30 stood at Rs 284 crore, stake-wise effective gross debt at Rs 2,025.3 crore and consolidated gross debt at Rs 2,400.5 crore.

The consolidated debt, the developer added, went up mainly on account of new special purpose vehicles (SPVs) being consolidated. PML’s total debt figure across all SPVs edged up to Rs 3,167.4 crore in the April-June quarter compared with Rs 3,117.6 crore in the previous quarter.

There are some new launches in the pipeline, which may add up to approximately three million square foot (msf) spanning over 2013-14 to 2014-15. The rollouts will be spread over cities like Bangalore (1.4 msf), Chennai (0.4 msf) and Pune (0.4 msf).

Analysts put FY14 (estimated) at 1.4 msf and value at Rs 1,550 crore.

“Since the bulk of the new launches are in the premium segment, the success remains a key re-rating trigger,” said Parikshit Kandpal and Varun Chakri, research analysts with Karvy Stock Broking, in a June-end report.

Larsen and Toubro Ltd seeks to double overseas orders

This story first appeared in DNA Money edition on Friday, Aug 23, 2013.

Larsen and Toubro Ltd (L&T) is working on a template to more than double its international order flow this fiscal.

This, it feels, will go a long way in maintaining operating profit margins at 11-11.5% this year, given an overall financial weakness affecting the Indian infrastructure industry.

A M Naik, group executive chairman, L&T, said the management has worked aggressively on building a strong organisation outside India to bag infrastructure projects. “We are targeting order inflows of Rs30,000 crore in this fiscal. As challenges become more intense in the domestic market, we are focusing overseas.

Our strategy is to do as many projects in international markets as possible. This will help us overcome the overall slowdown experienced in the domestic market,” he said at the company’s 68th Annual General Meeting in Mumbai on Thursday.

In the next few days, the company is expecting Rs3,500 core worth of orders from Qatar in the power transmission and sub-station space. Another Rs1,500 crore to Rs2,000 crore worth of road projects from Doha, in addition to a metro project, is in the works.

The company sees a bulk of these international orders coming in from the Middle East. It’s also targeting the Commonwealth of Independent States (CIS) and Far East markets, thus widening its scope for any overseas business opportunity. The current domestic to international order flow mix in the company now stands at 75:25.

In fact, the infrastructure major has started to sharpen its focus on international orders over the last couple of years.

For instance, its order book stood at Rs6,000 crore, excluding IT, engineering and exports of products, in fiscal 2012 and the company achieved a figure of Rs12,000 crore in the last fiscal.

There have been some earlier reports that L&T is weighing divesting stake in Dhamra Port Company Ltd – L&T currently owns 50% through its subsidiary, Infrastructure Development Projects Ltd (IDPL) and the balance is owned by Tata Steel. Clearing the air, Naik said discussions (for IDPL stake sale) are still going on.

“In the current economic situation, valuations tend to get depressed. We are not in a distressed sale position. If we get the right value, we will go ahead with plans to dilute up to 20%,” said Naik.

The company management has clarified that it has no overseas fund raising plans citing strong cash flows and will be able to meet funding requirements. At a group level, the company debt stands at Rs60,000 crore, much of which comes from financial services and concessions business.

On how much of the debt is hedged and vice-versa, R Shankar Raman, CFO, L&T, said, “The debt is largely in Indian rupee (INR) as the revenue profile is INR as a result the question of hedging a significant portion doesn’t arise for the group,” he said adding that earning more dollars will be the best bet to deal with the depreciating INR.

Naik added, “The current situation in terms of economic development is not good at all. People say that the gross domestic product (GDP) growth is around 5% and sometimes one wonders if it is really the case looking at what is really happening on ground at present. The INR is reaching a new low on a daily basis and we really have no idea how further down will it go. The infrastructure sector has been going through troubled times since the last over two years now and I don’t see any improvements (in terms of possible economic recovery) in the next one year or so,” he said.

The company is restructuring its engineering and services business (a major part within L&T). A new subsidiary -- L&T Technology Services Ltd -- is being formed which will buy over the engineering piece which is with L&T Infotech.

“We will then transfer -- at the right time between now and April 1, 2014 -- within engineering also in that company thus making it a technology services company. This will make us a very strong engineering service provider. It’s too early to say if we will be listing that company,” said Naik.
 

Shot in arm for Wockhardt as pledged shares released

This story first appeared in DNA Money edition on Wednesday, Aug 21, 2013.

Drug-maker Wockhardt said its promoters and promoter-entities have completely released shares pledged by them earlier.

Over 6.97 crore shares held by Khorakiwala Holdings and Investments and another 442,785 shares held by Habil Khorakiwala were released. With this, promoters have no more shares pledged in the market.

Wockhardt did not share other details.

Analysts said the release of pledged shares is a positive for the stock, but it does not end troubles for the company.

Bhavika Thakker, research analyst with IIFL, said the June quarter has not been kind to the company.

One bad news followed another: US drug regulator FDA issued ‘Form 483’ – it is a post-inspection record of violations of quality or safety norms at the drug manufacturing plant – last week to Wockhardt’s Chikalthana unit, which contributes the largest chunk to the company’s revenues; before that, there was a warning letter; then, an FDA import alert for the Waluj facility. Even the UK drug regulator was not happy with the Chikalthana unit.

Consequently, Wockhardt’s stock plummeted 77% this fiscal so far (from Rs2,005.80 on April 1 to Rs454.25 on Tuesday).

“Release of the promoters’ pledged shares is just a short-term measure. I’d still advise a wait-and-watch approach on this stock. There are some serious operational issues that need to be addressed by the management to bring back confidence in the market,” said Thakker.

Analysts said Wockhardt now looks like a beaten-down stock. Although some traders may perceive in it a counter-bet, the stock does not make for a good pick from an investment perspective, they said.

“Any bad news from the Chikalthana facility will see the stock getting battered,” said an analyst. To preempt any such situation, Wockhardt has got on board the US-based Lachman GMP Consultant to assist it in reviewing all the regulators’ observations.

Tony Fernandes eyes railway hotels

This story first appeared in DNA Money edition on Monday, Aug 19, 2013.

Hospitality companies including Tune Hotels, owned by AirAsia promoter Tony Fernatndes, are in the race for setting up hotels at 14 semi-developed sites near key railway stations across the country.

Ircon International, a company under Railways, is offering multi-functional complexes (MFCs) that feature hotel rooms, designated space for food and beverage and operations facilities at key railway stations across India.

The total guest room inventory across these hotels is expected to be over 600.

Tune Hotels India Services (THIS) operates as a 60:40 joint venture between Tune Hotels and Mumbai-based Apodis Hotels and Resorts Ltd. While Apodis holds the master franchise for Tune-branded hotels in India, the management of these properties will be handled by THIS, which will also look after technical and development services and project management consultancy.

Apodis Hospitality Group, which also owns and operates bed-and-breakfast hotel chain Mango Suites along with Cafe XO restaurants, confirmed it is in the bidding participation.

Umesh Luthria, executive director and CEO, Apodis Hospitality Group, said the company is working on the tender document. “We are looking into the legalities of the tender document while simultaneously assessing the market demand. If it is an over 100-room hotel, then we will go with Tune brand and if the location has a smaller inventory of 50-70 guestrooms, then it will be Mango Suites,” he said.

The 14 sites are in Jammu, Allahabad, Haridwar, Udaipur, Jodhpur, Gwalior, Indore, Jabalpur, Raipur, Digha, Siliguri, Hubli, Madurai and Kannur.

With railways offering hotel developments on their land parcels, industry experts said a huge opportunity awaits the hotel chains operating in India.

The projects are located in close proximity to railway stations and some of the sites even have space for meeting rooms, banquet halls, food courts, supermarkets, shops for pharmacies and ATMs.

Shreenath Shastry, national director-hospitality and leisure, Knight Frank (India), the company which is handling the bidding process, said, “The organised segment will see value in the sites on offer because of prominent locations, clear title developments and ready markets.”

Sanjay Sethi, MD & CEO of Berggruen Hotels, said, “It will give an opportunity to a lot of new, improved, competitive and quality products to address the market. I’ll be very keen to explore this opportunity. While not all sites will be viable, at least 20-30% of the locations on offer would certainly make for ideal locations,” he said. Berggruen is in the process of creating a separate brand to tap the ever-growing budget and economy travellers, he said.

Industry sources said the 14 sites are only the first tranche. In all, there are over 100 developments in various stages of  planning and development.

Tata Group’s Ginger, Accor’s Formule 1 and Lemon Tree’s Red Fox are the other major players in the budget hotel segment, and are likely to participate in the bidding process as well.

The final date for submission of the bids is September 5 and the technical bids will be opened the next day.

Sunday, 18 August 2013

Aman gives fillip to DLF debt-cut plan

This story first appeared in DNA Money edition on Friday, Aug 16, 2013.

Despite slowdown in the hospitality business, Aman Resorts, realty major DLF’s hospitality chain, has seen significant improvement in both operations and perceived valuation, lifting the parent’s hopes of selling Aman profitably and cut its own heavy debt.

In fact, the hotels business has contributed Rs 10.4 crore to DLF’s first quarter consolidated net profit of Rs 181 crore, a turnaround from loss-ridden quarters of last fiscal.

In an earnings call, Ashok Tyagi, group CFO, DLF, cited improved operations and better foreign exchange translation as key reasons for Aman operations turning profitable.

To divest non-core assets and reduce debt, DLF agreed to sell the Aman Resorts portfolio (excluding Aman Hotel, Delhi) back to its founder Adrian Zecha for $300 million.

Zecha was, however, not able to arrange the funds in time, leading to expiry of the exclusivity period in June. The DLF management later initiated discussions with a few other buyers even as Zecha remains in the fray.

Tyagi said the company was confident of closing the Aman Resorts deal soon and that the transaction will be value-accretive compared to its earlier valuations.

Saurabh Chawla, ED-finance, DLF, said, the hotel business will likely post an Ebitda number of $20 million this fiscal on the back of  “an exceptionally good January-June period” and given that the group is “slated to open four properties across the globe”.

The DLF management will be expecting increase in the valuation of Aman Resorts, considering that new hotels / resorts in international markets like Italy, China, Vietnam and Jordan will be added to its portfolio, and the business has also started generating profits.

Cox & Kings expects windfall from Rupee fall

This story first appeared in DNA Money edition on Friday, Aug 16, 2013.

Travel and tour operator Cox & Kings said it is expecting to benefit in a big way from the depreciating rupee, which has cut costs for inbound tourists.

Peter Kerkar, Group CEO, Cox & Kings, said, “The benefit of rupee decline helps us because a large percentage of our revenues is in foreign currency. The initial signs are showing travel to India should certainly become more attractive.”

While the gains were not reflected in the first quarter results, company officials said the real fall in rupee against dollar came in June and hence the impact will be visible in the upcoming quarters.

With the Indian travel, tourism and hospitality sectors set to enter the peak season from October, industry players are gung-ho on the prospects.

“India is finally looking affordable from a global perspective. We are hoping that our last two quarters of the current fiscal — when our international offices send business to India as well as the incoming traffic into the country — should be boosted by this current situation,” Kerkar said in an recent earnings call.

On the other hand, Anil Khandelwal, CFO, Cox & Kings, said the company hasn’t seen any slowdown in terms of leisure holidays.

“People will continue with their travel plans irrespective of depreciating rupee against the dollar. That’s because, people basically keep a budget for travel in their mind and plan their holidays accordingly,” said Khandelwal.

According to Union tourism ministry, foreign tourist arrivals were up by 1.9% to 12.8 lakh despite April-June quarter being a lean season.

Wockhardt says one more unit under FDA scanner

This story first appeared in DNA Money edition on Thursday, Aug 15, 2013.

Pharma major Wockhardt’s regulatory troubles over its manufacturing facilities do not seem to end.

After its Waluj unit in Aurangabad,  foreign regulators have  expressed concerns over its the largest revenue contributing unit of Chikalthana in the same district.

According to a senior Wockhardt official, both US Food and Drug Administration (FDA) and the UK Medicines and Healthcare Products Regulatory Agency (MHRA) had conducted inspections at its Chikalthana, Shendra and Waluj Cephalosporin plants in July.

“The Chikalthana plant was jointly inspected by USFDA and MHRA in the last week of July and they have raised observations. We have 483s, some of them are more serious and some are minor in nature. We are reviewing all the questions and observations and will respond to the FDA next week,” the official said on an earnings call.

No critical observations were recorded by the MHRI for Wockhardt’s Shendra plant that caters to the UK, Irish and the US markets. The USFDA is expected to inspect the Shendra facility next month. The inspections by the regulators at its Waluj Cephalosporin plant were satisfactory, said the official.

For fiscal 2013, the Chikalthana facility contributed $230 million to the company’s sales.

India Cements cuts capex to Rs 250 crore

This story first appeared in DNA Money edition on Wednesday, Aug 14, 2013.

India Cements has cut its capital expenditure plan of Rs 300 crore by Rs 50 crore, company officials said on a recent earnings call.

“The company’s current gross debt stands at Rs 3,230 crore and the company doesn’t intend to spend on capacity expansion in fiscal 2014. However, it may look at expansion over the next 2-3 years,” Mihir Jhaveri and Prateek Kumar, analysts at Religare Institutional Research, said in a company note on Monday.

The capex in this fiscal would largely be spent towards maintenance and some debt reduction.

In the first quarter, India Cements spent towards capex of Rs 60 crore, while it was Rs 530 crore for the entire last fiscal.

The company’s profitability was hit due to weak realisation despite its industry leading volume take-off in Q1. The company’s sales increased 3% on-year to Rs 1,240 crore, but its operating profit and net profit declined 31% and 59% yoy to Rs 193 crore and Rs 43.9 crore, respectively.

Rajesh Kumar Ravi, analyst, Karvy Stock Broking, said in his company note said while sales volume rose 11% yoy (as compared with industry growth of 3-4%), the company’s net realisation declined 1% quarter on quarter and 6% yoy.

“This was despite cement price improvement in Andhra Pradesh market during later part of the first quarter. Net realisation decline (3% below our estimate) resulted in Ebitda decline of 31% yoy (versus our estimate of 19% decline) and adjusted net profit decline of 59% yoy (versus our estimate of 39% decline).”

Eros to finalise NYSE IPO by August-end

This story first appeared in DNA Money edition on Wednesday, Aug 14, 2013.

Eros International, a leading global media and entertainment company, is likely to finalise its New York Stock Exchange (NYSE) listing plan by this month-end.

The company had filed for an initial public offering (IPO) for $250 million with the US Securities and Exchange Commission in March last year.

Eros International has a BSE-listed subsidiary / associate company called Eros International Media (EIML). The latter’s officials could not be reached for comment.

An industry source, however, said EIML is very likely to disclose the NYSE listing details at its annual general meeting on August 28.

In another development, EIML has partnered with YM Movies of music luminary A R Rahman to produce a Hindi feature film which will mark the latter’s debut as a film producer.

“It is a 16-year relationship with Eros and this time it is extending the role a bit more. It is about exploring the other side of creative partnership,” said Rahman in a statement.

The yet-to-be-titled film has been conceived and written by Rahman with help from international and local talent and will celebrate youth’s sensual love, art and self-discovery.

IHCL sees room rates rising in Oct

This story first appeared in DNA Money edition on Tuesday, Aug 13, 2013.

Indian Hotels Co Ltd (IHCL), the Tata group hospitality flagship, has reported a 42.42% decline in consolidated net loss at Rs19 crore in the first quarter fiscal 2014 over corresponding quarter last year. Total income from operations during the April-June quarter was 7% higher at Rs908 crore on year.

Anil P Goel, executive director-finance, IHCL, said the company saw an occupancy of 59% across the portfolio of hotels in India. “The average room rate (ARR) for the quarter at Rs8,300 was slightly lower as compared with the last year.

Operating margins, at 11%, were in line with last year. We have been able to bring down financing costs by 23% over the previous fiscal,” he said.

With the Indian hospitality set to enter the business season in the next 45 days, the company is hopeful of marginally increasing the room rates.

Deepa Misra, senior vice president–sales and marketing, IHCL, said there has been an overall 20% increase in supply of hotel rooms during April–June, 2013 over last year.

“Most of the new supply (about 69%), has come in the upper upscale, upscale and midscale segments and 28% in luxury (largely Chennai and Hyderabad). Demand growth has been 17% for this period. However it is still trailing supply growth by 3% which has had an impact on the hotel industry occupancy and average room rates (ARRs),” she said.

On the international business front, Goel said the portfolio has performed very well with all the three hotels in the US reporting encouraging results in the first quarter.

“Both Boston ($300 - ARR) and San Francisco ($300 - ARR) have touched 80% occupancy while it is 77% at The Pierre ($640 - ARR) against 65% last year. We will be looking to increase the ARRs in these markets.

“The UK market has been quite stable, Maldives is likely to stabilise by the time we get into the business season, hotels in Sri Lanka, Malaysia, Bhutan and Sydney are doing fine as well,” said Goel.

As of August 2013, the company has a total inventory of 14,506 rooms. In the current fiscal, IHCL will add 12 hotels (mainly through management contracts) and inventory of 1,575 rooms.

Dish TV plans domestic sourcing of set-top boxes to offset rupee drop

This story first appeared in DNA Money edition on Monday, Aug 12, 2013.

Dish TV, India’s top direct-to-home (DTH) operator, is considering domestic sourcing of digital set-top-boxes (STBs) to offset rising costs due to rupee depreciation.

A flagging rupee has been an industry-wide concern for a while now, calling for efforts to control the related impact on business, the company’s top official said.

Jawahar Goel, managing director, Dish TV India, said on a recent analyst call, “Given the depreciating rupee, we are evaluating possibilities for improvement in hardware economics of consumer premises equipment (CPE) sourced from India. We have also been considering options with our overseas suppliers to commence production at a base in India.”

Last month, Dish TV had taken a price hike of `250 per STB to bridge the widening gap between cost of CPE and the amount realised from the customer.

Other DTH players such as Tata Sky, Airtel Digital and Reliance Digital followed suit by increasing prices broadly in the same range.

Also, in this year’s Budget, Union finance minister P Chidambaram had hiked customs duty on imported STBs from 5% to 10%. Considering there aren’t many domestic manufacturers of STBs for the digital cable and DTH sectors, the government’s decision to make imported STBs expensive was seen as a move to incentivise domestic manufacturing and bringing more players in the market.

Among the few local STB manufacturers are Noida-based Dixon Technologies, Kortek Electronics and Videocon Industries. International players including Hampshire-based Exset are understood to be exploring tie-ups with Indian manufacturers to produce STBs here.

Industry experts said Dish TV’s move to source STBs locally may be followed by other players, experts said.

“We have a hunch that in the near future there can be a higher duty on import, because of the balance of payment issues. In fact, we have already alerted our vendors to set up shop, to convert and produce the STBs locally. We are not buying new STBs for next 3-4 months as we have enough stock. And by that time the vendors are likely set up shop in India,” said Goel.

Dish TV currently has an inventory of 1.4 million STBs and another 0.6 million with the channel partners. At `60 a dollar, the total cost of the CPE, company officials said, is close to `2,700 for a standard definition set. DTH players have been offering STBs at a subsidised cost to attract subscribers but are gradually expected to move towards a zero-subsidy model by increasing prices. Commenting on the possibilities, R C Venkateish, CEO, Dish TV India, said,

“We are moving towards elimination of subsidies in the next one to two years. So certainly a combination of efforts to reduce costs as well as increase prices will be used. Local manufacturing will play a crucial role towards this. While it is not a very big chunk, even a couple of hundred rupees of savings will go further towards reduction of subsidies.”

He said the company is focused on increasing value delivery to the customer and is coming up with innovations. “New products will be introduced in the second half, which will further position us separate from cable,” he said.

Lupin sets up R&D in US, ropes in Teva, Sandoz executives

This story first appeared in DNA Money edition on Saturday, Aug 10, 2013.

Lupin, the country’s third largest pharmaceutical company, has just begun setting up a research and development (R&D) centre in the US, but the R&D head of Teva Pharmaceuticals and another top official from Sandoz, the generic pharmaceuticals division of global industry leader Novartis, are on board already.

Lupin is identifying other key officials and expects to get the R&D centre operational around August next year.

Vinita Gupta, CEO of Lupin, said the company started working on the US R&D project six months ago. “It’s a work in progress. We are attracting top-notch research and business development talents for this facility. Some key officials have come on board in the last quarter and they are working on putting together plans and partnerships. Our goal is to get the products in the respiratory and dermatology segments into the market as soon as possible.”

Another reason for the R&D unit in the US, she said, is that it “help us to undertake research of controlled substances, something we can’t do outside of the US because of their import barriers”.

On an average, the company spends 7.5-8% of its net sales on R&D. Last fiscal, it spent Rs 709.80 crore. Some 9% of Lupin’s 13,000 staff worldwide are in the R&D space.

Desh Bandhu Gupta, founder and chairman of Lupin, said, “We’ve been learning a lot from our domestic R&D centres. The US facility will add to this overall learning and the drug discovery process.”

Lupin has invested Rs 2,778 crore in the last six years in R&D. It has two R&D centres in India: Lupin Bioresearch Centre in Pune, a centralised set-up with 1,400 scientists,  and Lupin Research Park in Aurangabad, a smaller facility with 50-60 employees. The Pune centre’s biotechnology group has already received its first marketing authorisation for an oncology product. It received milestone payment of $6.5 million for two products being jointly developed with Medicis Pharmaceutical Corporation.

The centre is conducting bioequivalence studies for its generic products and branded formulations, and has completed 19 full studies last fiscal, taking the overall tally to 83. It filed for 157 new patents last fiscal, taking the overall total to 1,181.

Lupin targets 50% sales from brands

This Q&A first appeared in DNA Money edition on Thursday, Aug 8, 2013.

Lupin Ltd reported 43% increase on-year rise in the first-quarter net profit at Rs 401.1 crore. Analysts, however, were not impressed over 5% fall in domestic revenues and 12% sales drop in Japanese market, which led to the stock falling 6.5% on Wednesday. Vinita Gupta, CEO, Lupin Pharmaceuticals Inc and group president & CEO elect, Lupin Ltd, spoke about the Street's concerns and expansion plans. Excerpts from the interview:

On first quarter results
The concern is that a big part of our income about Rs 100 crore is other income. But the P&L is presented in a way that it captures just one part of the foreign exchange impact.
The Rs 100 crore is primarily forex impact on transaction gain and the other lines in the P&L capture the expenditure. So, the net forex impact is Rs 30 crore. Besides, this is also after a long time when our revenue grew in single digit. The reason primarily is the slowdown in India business, the US business grew 20% in dollar terms and 25% in rupee terms. India has been a challenge with National List of Essential Medicines, which came into effect in June. Our Japan business grew 5% in yen terms but yen depreciated so in rupee terms we had an impact.

On next level of growthWe have a host of growth drivers. On the generic side -- in the US as well as other parts of the world like Japan -- we have a huge pipeline of over 175 products, of which only about 50 have come into the market. We are also working on growing the pipeline and investing in differentiated platforms that will help us in long-term growth for the generics business.

On new drug discovery plansOur biggest differentiator is we are trying to build, will be the Novel Drug Discovery and Development (NDDD) programme. Our efforts are directed towards identifying and developing new therapies for areas including metabolic/endocrine disorders, pain and inflammation, autoimmune diseases, CNS disorders, cancer and infectious diseases. We have a portfolio of 10 novel compounds that are moving through a robust pipeline from discovery to development.

On specialty / branded businessWe are trying build the brand business in the US to start with and have also started looking at other markets. If you look at our business 60% is generics and the balance is branded. The branded business is more profitable compared to generics hence is more sustainable in the long term. It is our endeavour to make branded 50% or more.

On Alinia deal with RomarkWe have acquired rights for US market for Alinia drug from Romark. We have partnered with them on the oral suspension which is focused on the pediatric market. They were doing $2 million in the pediatric market and we have taken over that revenue and would build it from here. While the overall market for that drug is $2 billion the pediatric part is small and we think we have a very good product to be able to get a good share.